{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-003166","form_type":"8-K","ticker":"OSTX","cik":"0001795091","company_name":"OS Therapies Inc","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.202561+00:00","generated_at":"2026-05-16T10:55:11.174204+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"OS Therapies raises $7.53M via warrant exercise inducement from all 9 existing holders","bullets":["Gross proceeds of $7.53M from exercise or pre-funding of 5,382,148 Existing Warrants at $1.40/share.","New Warrants issued for up to 5,382,148 shares at $1.40, exercisable immediately for 5 years.","Net proceeds to fund OST-HER2 BLA/MMA filings, commercial prep, and OS Animal Health spinoff.","BLA for OST-HER2 in metastatic osteosarcoma expected by end of January 2026 under Accelerated Approval.","Company expects cash runway into 2027; all 9 accredited investors offered agreed to participate."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-003166","json":"https://secwatch.observer/filing/0001213900-26-003166.json","markdown":"https://secwatch.observer/filing/0001213900-26-003166.md","text":"https://secwatch.observer/filing/0001213900-26-003166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1795091/000121390026003166/0001213900-26-003166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1795091/000121390026003166/ea0272516-8k_ostherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:55:11.174204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b7073d76902db7934fa67e9d8ef7cd57ed14ff0c","claim":"OS Therapies Inc entered into Inducement Letters with less than 10 accredited investors valued at approximately $7.5 million (effective 2026-01-10).","evidence_excerpt":"On January 10, 2026, OS Therapies Incorporated (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with less than 10 accredited investors (the “Holders”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390026003166/0001213900-26-003166-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"less than 10 accredited investors"},{"label":"Value","value":"approximately $7.5 million"},{"label":"Effective","value":"2026-01-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}